These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35836189)

  • 1. The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19.
    McCrae K; Glegg S; Goyer MÉ; Le Foll B; Brar R; Sutherland C; Fairbairn N
    Harm Reduct J; 2022 Jul; 19(1):77. PubMed ID: 35836189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "COVID just kind of opened a can of whoop-ass": The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada.
    Glegg S; McCrae K; Kolla G; Touesnard N; Turnbull J; Brothers TD; Brar R; Sutherland C; Le Foll B; Sereda A; Goyer MÈ; Rai N; Bernstein S; Fairbairn N
    Int J Drug Policy; 2022 Aug; 106():103742. PubMed ID: 35679695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada.
    Moshkforoush M; DeBeck K; Brar R; Fairbairn N; Cui Z; Milloy MJ; Buxton J; Oldenburger T; McLellan W; Kendall P; Sedgemore K; Wilson D; Kerr T; Hayashi K
    Harm Reduct J; 2022 May; 19(1):50. PubMed ID: 35614440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It's just a perfect storm": Exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances.
    Foreman-Mackey A; Xavier J; Corser J; Fleury M; Lock K; Mehta A; Lamb J; McDougall J; Newman C; Buxton JA
    BMC Public Health; 2023 Apr; 23(1):640. PubMed ID: 37013524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights from Drug Checking Programs: Practicing Bootstrap Public Health Whilst Tailoring to Local Drug User Needs.
    Ondocsin J; Ciccarone D; Moran L; Outram S; Werb D; Thomas L; Arnold EA
    Int J Environ Res Public Health; 2023 May; 20(11):. PubMed ID: 37297603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribed safer supply during dual public health emergencies: a qualitative study examining service providers perspectives on early implementation.
    McCall J; Hobbs H; Ranger C; Cameron F; Stuart H; Nelken J; Majalahti J; Urbanoski K; Kolla G; LeMaistre J; Toombs K; Herriot R; Pauly B
    Subst Abuse Treat Prev Policy; 2024 Mar; 19(1):19. PubMed ID: 38444035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada.
    Ali F; Russell C; Nafeh F; Rehm J; LeBlanc S; Elton-Marshall T
    Int J Drug Policy; 2021 Jul; 93():103237. PubMed ID: 33893026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging the Gap in Harm Reduction Using Mobile Overdose Response Services (MORS) in the Context of the COVID-19 Pandemic: A Qualitative Study.
    Seo B; Rioux W; Rider N; Teare A; Jones S; Taplay P; Ghosh SM
    J Urban Health; 2024 Apr; 101(2):252-261. PubMed ID: 38514599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supporting Self-isolation for COVID-19 With "Risk Mitigation" Prescribing and Housing Supports for People Who Use Drugs: A Case Report.
    Hong RH; Brar R; Fairbairn N
    J Addict Med; 2022 Sep-Oct 01; 16(5):592-594. PubMed ID: 35149612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community partner perspectives on the implementation of a novel safer supply program in Canada: a qualitative study of the MySafe Project.
    Mansoor M; Foreman-Mackey A; Ivsins A; Bardwell G
    Harm Reduct J; 2023 Apr; 20(1):61. PubMed ID: 37118799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site.
    Kolla G; Tarannum CN; Fajber K; Worku F; Norris K; Long C; Fagundes R; Rucchetto A; Hannan E; Kikot R; Klaiman M; Firestone M; Bayoumi A; Laurence G; Hayman K
    Harm Reduct J; 2024 Jan; 21(1):17. PubMed ID: 38243267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responding to Ontario's Overdose Crisis in the Context of the COVID-19 Pandemic.
    Gomes T; Kitchen S; Campbell T; Murray R; Leece P; Kolla G
    Healthc Q; 2022 Jul; 25(2):7-12. PubMed ID: 36153678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "If it wasn't for them, I don't think I would be here": experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis.
    Kolla G; Pauly B; Cameron F; Hobbs H; Ranger C; McCall J; Majalahti J; Toombs K; LeMaistre J; Selfridge M; Urbanoski K
    Harm Reduct J; 2024 Jun; 21(1):111. PubMed ID: 38849866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing safe supply: ethical considerations for clinicians.
    Duthie K; Mathison E; Eyford H; Ghosh SM
    J Med Ethics; 2023 Jun; 49(6):377-382. PubMed ID: 35985806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of Safe Supply Alternatives During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada, 2021.
    McNeil R; Fleming T; Mayer S; Barker A; Mansoor M; Betsos A; Austin T; Parusel S; Ivsins A; Boyd J
    Am J Public Health; 2022 Apr; 112(S2):S151-S158. PubMed ID: 35262376
    [No Abstract]   [Full Text] [Related]  

  • 16. "As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.
    Jaffe K; Blawatt S; Lehal E; Lock K; Easterbrook A; MacDonald S; Harrison S; Lajeunesse J; Byres D; Schechter M; Oviedo-Joekes E
    Harm Reduct J; 2023 Apr; 20(1):51. PubMed ID: 37060027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings.
    MacKinnon L; Socías ME; Bardwell G
    J Subst Abuse Treat; 2020 Dec; 119():108153. PubMed ID: 33032862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol.
    Nosyk B; Slaunwhite A; Urbanoski K; Hongdilokkul N; Palis H; Lock K; Min JE; Zhao B; Card KG; Barker B; Meilleur L; Burmeister C; Thomson E; Beck-McGreevy P; Pauly B
    BMJ Open; 2021 Jun; 11(6):e048353. PubMed ID: 34108170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study.
    Galarneau LR; Hilburt J; O'Neill ZR; Buxton JA; Scheuermeyer FX; Dong K; Kaczorowski J; Orkin AM; Barbic SP; Bath M; Moe J; Miles I; Tobin D; Grier S; Garrod E; Kestler A
    PLoS One; 2021; 16(7):e0255396. PubMed ID: 34324589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How an emergency department is organized to provide opioid-specific harm reduction and facilitators and barriers to harm reduction implementation: a systems perspective.
    Jiao S; Bungay V; Jenkins E; Gagnon M
    Harm Reduct J; 2023 Sep; 20(1):139. PubMed ID: 37735432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.